OVERVIEW
The promise that gene therapy offers patients with hemophilia has been tempered by the risks and unknowns of this new type of approach. Now, the results of phase 3 trials are starting to emerge, and our understanding of gene therapy is deepening. In this series, faculty experts will discuss the latest data on gene therapy along with the implications of gene therapy for patient care.
GOAL STATEMENT
The goal of this activity is that learners will be better able to understand gene therapy and to integrate gene therapy into the clinical care paradigm for patients with hemophilia.
LEARNING OBJECTIVES
Upon completion of this activity, participants will: Have increased knowledge regarding the [LIST] [ITEM]Clinical trial data on gene therapy for hemophilia [ITEM]Implications of gene therapy in the management of hemophilia [/LIST] Demonstrate greater confidence in their ability to [LIST] [ITEM]Implement gene therapy in an interprofessional care team environment [/LIST]
ACCREDITATION STATEMENT
In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. [JALOGO] [MEDSCAPE]
[bold]For Physicians[/bold] Medscape, LLC designates this live activity for a maximum of 1.0 [italic][bold]AMA PRA Category 1 Credit(s)™[/bold][/italic]. Physicians should claim only the credit commensurate with the extent of their participation in the activity. [bold]For Nurses [/bold] Awarded 1.0 contact hour(s) of nursing continuing professional development for RNs and APNs.
Supported by an independent educational grant from [bold]CSL Behring[/bold] and [bold]Spark Therapeutics[/bold].
Organized by
